[ NATIONAL · SG ]
A health sciences authority that combines product regulation with forensic science and national blood services under one roof.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
ASIA-PACIFIC
The Health Products Act 2007, in its 2020 Revised Edition — a revision incorporating all amendments up to and including 1 December 2021 and coming into operation on 31 December 2021. Its long title is precise about the reach: an Act to regulate the manufacture, import, supply, presentation and advertisement of health products and of active ingredients used in the manufacture of health products. The Act commenced on 1 November 2007, with the exception of Part 14, whose commencement was left to ministerial notification in the Gazette.
Through the Health Sciences Authority, administering the Act and the subsidiary legislation made under it. Singapore has been a PIC/S Participating Authority since January 2000, and the HSA is the participating body. The Act regulates activities rather than only products: manufacture, import, supply, presentation and advertisement are each a controlled activity, so an organisation can fall inside the Act by advertising a product it does not make.
WHAT TRANSFERS
GMP inspection confidence transfers through PIC/S; the obligations under the Act do not. Two features of the drafting catch organisations out. First, active ingredients are in scope in their own right — the long title names them alongside health products, so an upstream supplier is not outside the Act by virtue of never handling a finished product. Second, presentation and advertisement are regulated activities, which places marketing material inside the same statute as manufacture rather than in a separate consumer-protection regime. Neither of those follows from being compliant elsewhere, and neither is discharged by an inspection outcome recognised through PIC/S.
Manufacture, import, supply, presentation and advertisement are named separately in the long title. Mapping an operation against all five is the first step, because an organisation frequently performs more of them than it thinks it does.
The Act reaches active ingredients used in the manufacture of health products, defined as substances usable as a pharmacologically active constituent. Suppliers who consider themselves chemical manufacturers rather than health-product manufacturers are still inside the scope.
The operative text is the 2020 Revised Edition as it stood after amendments to 1 December 2021, in force from 31 December 2021. Citing "the Health Products Act 2007" without the edition points at a text that has since been consolidated.
The Act commenced on 1 November 2007 except for Part 14, which was left to be appointed by notification in the Gazette. Assuming a whole statute is in force on its commencement date is a reliable way to cite a provision that was not.
The Health Products Act 2007, in its 2020 Revised Edition incorporating amendments up to 1 December 2021 and operative from 31 December 2021. It regulates the manufacture, import, supply, presentation and advertisement of health products and of the active ingredients used to make them.
Yes. The long title names active ingredients used in the manufacture of health products alongside the products themselves, and the Act defines an active ingredient as any substance or compound usable in manufacture as a pharmacologically active constituent. Supplying only active ingredients is not an exemption from the Act.
Yes, and it is a common surprise. Presentation and advertisement are named in the long title alongside manufacture, import and supply, so promotional material falls under the Health Products Act rather than under a separate advertising regime.
Yes. The Health Sciences Authority has been a PIC/S Participating Authority since January 2000. That supports mutual confidence in GMP inspection outcomes between participating authorities; it does not licence a site or displace any obligation under the Health Products Act.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Singapore: requirements still arrive through the authorities below, and the edition in force is theirs to state.
Participation changes which evidence transfers, and which edition of a harmonized guide the local instrument is likely to pin.